Inspire2Live
  • Home
  • About us
    • The patient’s voice
      • Origin story of Inspire2live
      • Mission & vision
      • How we work
      • What sets us apart
      • Partners
      • Social enterprises
      • Funding and financial stewardship
      • Organisation
    • Patient Advocacy
      • What is patient advocacy?
      • Meet our patient advocates
      • Patient stories
      • In memoriam
    • Contact
      • Find us on social media
      • Annual Reports
      • For the media
      • Get in contact
  • Our work
    • Our projects
      • DEEP Diagnostics
      • Access to medicine
      • Cancer registries
      • Discover all our projects
    • Congresses
      • Upcoming congresses
      • Annual congresses
      • Past congresses
    • World Campus
      • About the World Campus
      • World Campus sesssions
  • Our impact
    • Ambassadors
    • Heroes of cancer
    • Achievements
    • Research & development
    • Access and implementation
  • News
  • Join Inspire2live
  • Donate
Select Page
Home > News > In the media > Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper
Personalized Treatment for Hematologic Diseases in Europe: An EHA Position Paper
March 29, 2021

https://journals.lww.com/hemasphere/Fulltext/2020/10000/Personalized_Treatment_for_Hematologic_Diseases_in.8.aspx

More news

Exercise works for people living with cancer

August 18th, 2025

READ MORE

Why we must act

August 18th, 2025

READ MORE

Inspire2Live establishes an international initiative to provide access to essential cancer drugs for LMICs

July 10th, 2025

READ MORE

Navigation

Home

The patient’s voice

Patient advocacy

World Campus

Our impact

Research & development

More Inspire2Live

Our mission & vision

How we work

Partners

Congresses

News

ANBI statement

Join us

Donate

As a company

Become a patient advocate

Become a partner

Contact us

Follow on social media



Facebook



Twitter



LinkedIn



YouTube



Instagram

Disclaimer | Privacy statement | Cookie statement | ANBI number: 8220 32 752
Disclaimer | Privacy statement | Cookie statement | ANBI number: 8220 32 752